Drug Profile


Alternative Names: Bestrabucil; Busramustine; KM 2210; Kregan

Latest Information Update: 09 Jan 1995

Price : $50

At a glance

  • Originator Kureha Corporation
  • Class Antineoplastics
  • Mechanism of Action DNA inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Graft-versus-host disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Jan 1995 Discontinued-Preclinical for Graft-versus-host disease in Japan (Unknown route)
  • 07 Nov 1994 Discontinued-preregistration for Non-Hodgkin's lymphoma in Japan (PO)
  • 07 Nov 1994 Discontinued-preregistration for Breast cancer in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top